These extended-release treatments offer more options for medicated treatment of chronic OUD and therefore add importantly to the ability of combating the opioid epidemic. After the review of the evidence and the discussion of wide-ranging potential benefits and contextual considerations associated with critical treatment, the pricing of Sublocade, Probuphine, and Vivitrol in the U.S. health care system was judged to represent low value for the money. Greater efforts are necessary to aid in the alignment of the price of treatments with their demonstrated benefits to ensure sustainable access to high-value care for all patients.
